相关实验视频
Updated: Jun 3, 2025
00:09
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
Published on: August 21, 2019
7.0K
反复暴露于电离辐射会诱导TRIP13的表达,从而在肺癌细胞中产生放射电阻
Wenqing Liu1,2, Qijing Lei1,2,3, Ans M M van Pelt1,2
1Reproductive Biology Laboratory, Centre for Reproductive Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, 1105AZ, The Netherlands.
Scientific reports
|January 6, 2025
概括
肺癌细胞中的生殖细胞基因 (GC基因) 增强了DNA修复和抗辐射能力. 一个GC基因TRIP13通过促进DNA修复来驱动这种耐药性,从而影响非小细胞肺癌治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 辐射瘤学 辐射瘤学
背景情况:
- 放射治疗是一种标准的肺癌治疗方法,但耐药性限制了疗效.
- 胚胎细胞 (GC) 基因与肺癌细胞中增强的DNA修复和放射电阻有关.
- 在此之前,TRIP13在抗辐射方面的特定分子机制尚不清楚.
研究的目的:
- 研究TRIP13在非小细胞肺癌 (NSCLC) 辐射抵抗中的作用.
- 阐明TRIP13赋予抗电离辐射的分子机制.
主要方法:
- 在NSCLC患者中分析TRIP13表达水平和与预后的相关性.
- 在肺癌细胞中对TRIP13表达 (过度表达和淘汰) 的实验性操纵.
- 评估DNA双链断裂修复效率和辐射后的放射电阻.
- 研究下游DNA修复蛋白质,包括NBS1,RAD51 (同类重组) 和XRCC5 (非同类末端结合).
主要成果:
- 在放射治疗后预后不佳的NSCLC患者中,TRIP13表达升高.
- 重复照射会增加基底TRIP13水平和抗辐射性,这种抗辐射性可以通过TRIP13水平来调节.
- 提升的TRIP13与辐射诱导的DNA损伤的增强修复相关.
- TRIP13影响同源重组修复通路,涉及NBS1和RAD51,并在较小程度上通过XRCC5.5进行非同源末端连接.
结论:
- TRIP13是NSCLC治疗耐药性的关键驱动因素,特别是在辐射后.
- 通过增强同源重组介导的DNA修复,TRIP13促进对电离辐射的抗性.
- 了解TRIP13通路为克服NSCLC放射电阻提供了潜在的治疗点.
相关概念视频
01:35Mutations
33.6K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
33.6K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K